Now let me share more about each platform, starting with Chromium, the unambiguous leader in single cell analysis. All this so we can maximize and deliver on the incredible opportunity we have ahead. We're continuing to push our innovation engine with new capabilities in all 3 platforms, and we are working to improve scale, efficiency and operational excellence throughout the company. We are coming off the biggest and the most exciting year of product launches in our history, and our team is fully focused on driving adoption and ensuring customer success. Regionally, the Americas and EMEA teams saw improvement after a slowdown in the prior year period, while APAC came in to lower our expectations.Īs we look to the year ahead, it's all about execution and impact. These results reflect the momentum we're seeing across our spatial portfolio fueled by the recent launches in both Visium and Xenium and the strength in Chromium consumables. Then I'll turn the call over to Justin for a more detailed look at our financials, business trends and outlook for the rest of the year.Ģ023 is off to a solid start with first quarter revenue growing 17% year-over-year to $134 million. ![]() And I'll share why based on early yet overwhelmingly positive feedback we hear from our customers, we firmly believe Xenium is the best system for in situ analysis. Next, I will discuss our progress, momentum and the exciting opportunities we have ahead in each of our 3 platforms. On today's call, I will start with an overview of our first quarter performance across our leading portfolio of single cell and spatial technologies. Thanks, Cassie, and good afternoon, everyone. (Operator Instructions) With that, I will now turn the call over to Serge. We will host a question-and-answer session after our prepared remarks. Joining the call today are Serge Saxonov, our CEO and Co-Founder and Justin McAnear, our Chief Financial Officer. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release 10x Genomics issued today, and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. These statements involve material risks and uncertainties that could cause actual risks or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. So we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. If you have not received this news release or if you would like to be added to the company's distribution list, please send an e-mail to An archived webcast of this call will be available on the Investor tab of the company's website for at least 45 days following this call. Earlier today, 10x Genomics released financial results for the first quarter ended March 31, 2023. (Operator Instructions) I will now hand over to your host, Cassie Corneau. My name is Bruno, and I will be the operator of today. Hello, everyone, and welcome to the 10x Genomics' First Quarter 2023 Earnings Conference Call. ![]() ![]() Tejas Rajeev Savant Equity Analyst Morgan Stanley, Research Division Ruizhi Qin Analyst JPMorgan Chase & Co, Research Division Patrick Bernard Donnelly Senior Analyst Citigroup Inc., Research Division Michael Leonidovich Ryskin Director in Equity Research & Research Analyst BofA Securities, Research Division Matthew Carlisle Sykes Research Analyst Goldman Sachs Group, Inc., Research Division Mason Owen Carrico Research Analyst Stephens Inc., Research Division Kyle Alexander Mikson Analyst Canaccord Genuity Corp., Research Division Serge Saxonov Co-Founder, CEO & Director 10x Genomics, Inc.ĭaniel Anthony Arias MD & Senior Analyst Stifel, Nicolaus & Company, Incorporated, Research Divisionĭaniel Gregory Brennan Senior Tools & Diagnostics Analyst TD Cowen, Research Division Cassie Corneau Manager of IR and Strategic Finance 10x Genomics, Inc.
0 Comments
Leave a Reply. |